HOME >> BIOLOGY >> NEWS
Double-trouble: Cells with duplicate genomes can trigger tumors

The idea that a failure of proper cell division produces genomic instability and promotes the development of cancer was first proposed by German biologist Theodor Boveri in 1915. The fact that tumor cells often have abnormal numbers of chromosomes supports this theory, and two papers published by Harvard Medical School researchers provide new, more direct evidence to support this.

David Pellman, Harvard Medical School associate professor of pediatrics at Dana-Farber Cancer Institute and Children's Hospital Boston, and colleagues tested the theory by blocking cell division in cells that also lack the tumor suppressor gene p53, to generate tetraploid cells - cells that contain a double quota of chromosomes. Compared to their diploid counterparts, which have a normal set of chromosomes, tetraploid cells were more prone to generate tumors in mice, and these tumors showed genomic instability similar to many human cancers.

Another study by Randall King, HMS assistant professor of cell biology, shows how tetraploid cells can arise. He shows that inaccurate segregation even of a single pair of chromosomes - an error that does occur randomly will halt cell division and produce tetraploid cells. Together, these papers lend experimental support to Boveri's ideas that errors in cell division contribute to the development of cancer.


'"/>

Contact: Leah Gourley
public_affairs@hms.harvard.edu
617-432-0442
Harvard Medical School
14-Oct-2005


Page: 1

Related biology news :

1. Cells take risks with their identities
2. Cells re-energize to come back from the brink of death
3. Need oxygen? Cells know how to spend and save
4. Cells selectively absorb short nanotubes
5. Cells use noise to make cell-fate decisions
6. Cells in the lung clear the air to prevent lung damage
7. Cells passed from mother to child during pregnancy live on and make insulin
8. Cells, dyes and videotape: Online scientific methods journal incorporates multimedia
9. Cells use mix-and-match approach to tailor regulation of genes
10. Cells in mucus from lungs of high-risk patients can predict tumor development
11. Double trouble: Cells with duplicate genomes can trigger tumors

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Double trouble Cells with duplicate genomes can trigger tumors

(Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
(Date:7/23/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2015.  ... a decrease of 33% compared to $6.8 million in the ... of 2015 was $0.3 million, or $0.01 per diluted share, ... in the same period a year ago.  ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
(Date:7/27/2015)... YORK , July 27, 2015 ... today announced the winners of its annual Klerman ... research by scientists who have been supported by ... career scientists to pursue innovative ideas in neurobiological ... "proof" of concept for the early detection, treatment, ...
(Date:7/26/2015)... (PRWEB) , ... July 26, 2015 , ... ... of its VALIDATE® ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA ... Each VALIDATE® ANEMIA kit is prepared using the CLSI recommended “equal delta” method ...
(Date:7/24/2015)... 2015 Equity Research Institute has ... (NASDAQ: PDLI ), Arena Pharmaceuticals Inc. (NASDAQ: ... Biotherapeutics Inc. (NASDAQ: NWBO ), and Acorda Therapeutics ... PDL BioPharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PDLI ... at 5,146.41, down 0.49%, the Dow Jones Industrial Average ...
(Date:7/24/2015)... 24, 2015 The global ... USD 27.8 billion by 2022, growing at an estimated ... a new study by Grand View Research, Inc. Development ... to result in significant reduction in cost of sequencing ... and usage rates of next generation sequencing throughout the ...
Breaking Biology Technology:Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5
Cached News: